Other news to note
Elite Pharmaceuticals Inc., of Northvale, N.J., gained FDA acceptance of its new drug application for Sequestox (ELI-200), the company's lead opioid abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. The agency has set a PDUFA date of of July 14 for the drug.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST